{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:43:37Z","timestamp":1792428217847,"version":"4.5.0"},"reference-count":20,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the long-term effect of ixekizumab (IXE) on radiographic changes in the spine in patients with radiographic axial spondyloarthritis (r-axSpA) by measuring change from baseline through 2 years in modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), and to identify potential predictors of progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study evaluates patients from COAST-V (ClinicalTrials.gov: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02696785\">NCT02696785<\/jats:ext-link>, biologic disease-modifying antirheumatic drug\u2013na\u00efve) and COAST-W (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02696798\">NCT02696798<\/jats:ext-link>, tumor necrosis factor inhibitor\u2013experienced) who had mSASSS data at baseline in the originating studies and 108 weeks after baseline in the extension study COAST-Y (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03129100\">NCT03129100<\/jats:ext-link>). We examined the proportion of patients who did not have spinal radiographic progression through 2 years (108 weeks) of treatment with IXE (80 mg every 2 or 4 weeks) and the change from baseline to year 2 in mSASSS. Potential predictors of spinal radiographic progression were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among patients with evaluable radiographs who were originally assigned to IXE (n = 230), mean (SD) change in mSASSS from baseline at year 2 was 0.3 (1.8). The proportion of nonprogressors over 2 years was 89.6% if defined as mSASSS change from baseline &lt; 2 and 75.7% if defined as mSASSS change from baseline \u2264 0. Predictors of structural progression at year 2 (mSASSS change &gt; 0) were age \u2265 40, baseline syndesmophytes, HLA-B27 positivity, and male sex. Week 52 inflammation in Spondyloarthritis Research Consortium of Canada spine was also a predictor of radiographic progression at year 2 in patients with magnetic resonance imaging data in COAST-V (n = 109).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The majority of patients with r-axSpA receiving IXE had no radiographic progression in the spine through 2 years of treatment. Predictors were generally consistent with previous studies.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.210471","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:20:44Z","timestamp":1638364844000},"page":"265-273","source":"Crossref","is-referenced-by-count":34,"title":["Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e van der","family":"Heijde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-0913","authenticated-orcid":false,"given":"John D.","family":"Reveille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"2022062202300632000_49.3.265.1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","article-title":"Mechanism of new bone formation in axial spondyloarthritis","volume":"19","author":"Poddubnyy","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2022062202300632000_49.3.265.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2022062202300632000_49.3.265.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"2022062202300632000_49.3.265.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"2022062202300632000_49.3.265.5","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"2022062202300632000_49.3.265.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"2022062202300632000_49.3.265.7","doi-asserted-by":"crossref","first-page":"e000430","DOI":"10.1136\/rmdopen-2017-000430","article-title":"Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis","volume":"3","author":"Braun","year":"2017","journal-title":"RMD Open"},{"key":"2022062202300632000_49.3.265.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212377"},{"key":"2022062202300632000_49.3.265.9","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"2022062202300632000_49.3.265.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2022062202300632000_49.3.265.11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022062202300632000_49.3.265.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216118"},{"key":"2022062202300632000_49.3.265.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"2022062202300632000_49.3.265.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3824"},{"key":"2022062202300632000_49.3.265.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key128"},{"key":"2022062202300632000_49.3.265.16","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.86.2.420"},{"key":"2022062202300632000_49.3.265.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21337"},{"key":"2022062202300632000_49.3.265.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2949-3"},{"key":"2022062202300632000_49.3.265.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.30627"},{"key":"2022062202300632000_49.3.265.20","doi-asserted-by":"publisher","DOI":"10.1186\/ar2565"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T09:31:50Z","timestamp":1655890310000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,1]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.3899\/jrheum.210471"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210471","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}